Clinical trials: Brain Metastases From Solid Tumors
Leptomeningeal Metastases
Study of Proton Radiation to the Brain and Spinal Cord for Patients With Leptomeningeal Metastases
The purpose of this study is to find the safest and most effective dose for delivering proton beam to the space containing CSF, brain, and spinal cord, in treating leptomeningeal metastases.
- Trial name
- NCT03520504
- Testing
- Proton craniospinal irradiation (CSI)
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain Metastases From Solid Tumors
SMART Trial: Cognitive Sparing Brain Radiotherapy for Multiple Brain Metastases
The goal of this phase II randomized trial is to determine if Stereotactic Radiosurgery (SRS) or Cognitive Sparing WBRT (CS-WBRT) better preserves neurocognitive function than standard Hippocampal Avoidance WBRT (HA-WBRT) in…
- Trial name
- NCT07505979
- Testing
- SRS, CS-WBRT, HA-WBRT
- Volunteers
- 90 people
- Sponsor
- National Taiwan University Hospital
Brain Metastases
Phase I Study of Temozolomide, Valproic Acid and Radiation Therapy in Patients With Brain Metastases
This type of study is called a "Phase I study". Its purpose is to determine the side effects of the two medicines listed in this study when given together with whole brain radiation, and the highest dose of valproic acid that can…
- Trial name
- NCT00437957
- Testing
- Temozolomide, Valproic Acid, Whole Brain Radiation Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Brain Tumor Adult, Brain Metastases From Solid Tumors
Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer
This study investigates the effects of brain radiotherapy on cognitive function by evaluating plasma biomarkers and apolipoprotein E (APOE) genotype in patients with primary or metastatic brain tumors.
- Conditions
- Brain Tumor Adult, Brain Metastases From Solid Tumors, Brain Tumor, Primary, Brain Tumor
- Trial name
- NCT07226466
- Testing
- Blood sample, Brain magnetic resonance imaging (MRI), Brain Health Assessment
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, San Francisco
Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients.
- Conditions
- Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)
- Trial name
- NCT03423628
- Testing
- Radiation Therapy, AZD1390
- Where
- 11 sites in United States, Japan and 1 more
- Volunteers
- 159 people
- Sponsor
- AstraZeneca
Brain Metastases, Adult, Brain Tumor - Metastatic
Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction
The goal of this study is to evaluate the feasibility and effectiveness of same-day radiation planning and treatment. The study will shorten the time interval between radiation planning (radiation mapping) and radiation…
- Conditions
- Brain Metastases, Adult, Brain Tumor - Metastatic, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Extra-cranial Solid Tumors
- Trial name
- NCT07132190
- Testing
- Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Ayal A. Aizer, MD
Metastases to Brain
Comparative Evaluation of Two Different Radiosurgery
Randomized double arm phase III study to evaluate feasibility and safety of Gamma Knife radiosurgery and Linac Based (Edge) radiosurgery in brain metastatic patients
- Trial name
- NCT02355613
- Testing
- Radiosurgery with Gamma Knife Perfexion, Linac-based Radiosurgery with EDGE
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Istituto Clinico Humanitas
Brain Metastases From Solid Tumors
Comparison of the Therapeutic Effects of Methylprednisolone and Dexamethasone on Peritumoral Edema During Radiotherapy for Brain Metastases:
This study is a multicenter, open label, randomized controlled, adaptive phase II/III seamless design clinical trial aimed at comparing the efficacy and safety of methylprednisolone (MP) and dexamethasone (DEX) in the treatment…
- Trial name
- NCT07542288
- Testing
- Methylprednisolone (Corticosteroid), Dexamethasone
- Where
- China
- Volunteers
- 400 people
- Sponsor
- The Second Affiliated Hospital of Hainan Medical University
Intracranial Metastatic Disease From Any Solid Malignancy
Simulation-Free Hippocampal-Avoidance Whole Brain Radiotherapy Using Diagnostic MRI-Based and Cone Beam Computed Tomography-Guided On-Table Adaptive Planning in a Novel Ring Gantry Radiotherapy Device
Hippocampal-avoidance whole brain radiation therapy (HA-WBRT) limits radiation dose to the hippocampal-avoidance region while still delivering therapeutic doses of radiation to the whole brain.
- Trial name
- NCT05096286
- Testing
- Ethos Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
This randomized phase I/II trial studies the side effects and the best dose of RO4929097 (gamma-secretase/Notch signalling pathway inhibitor RO4929097) when given together with whole-brain radiation therapy or stereotactic…
- Conditions
- Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, HER2/Neu Negative, HER2/Neu Positive
- Trial name
- NCT01217411
- Testing
- Cognitive Assessment, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor Malignancies, Brain Metastases From Solid Tumors
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.
- Trial name
- NCT06136884
- Testing
- AO-252
- Where
- 6 sites in United States
- Volunteers
- 86 people
- Sponsor
- A2A Pharmaceuticals Inc.
Brain Metastases
Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors
The purpose of this study is to: Test the maximum tolerated dose (MTD) of Bendamustine with whole brain radiation therapy (WBRT) To determine the plasma pharmacokinetics (a blood test to see how much of the drug is getting into…
- Trial name
- NCT00879073
- Testing
- Bendamustine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Bendamustine and Radiation Therapy in Treating Patients With Brain Metastases Caused by Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as bendamustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00837928
- Testing
- bendamustine, laboratory biomarker analysis, Surgical Resection of Brain Metastases
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- John Grecula
Recurrent Brain Metastases, Progressive Brain Metastases
Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary
Cancer that has spread to the brain, or brain metastasis, is difficult to treat. Meclofenamate is a drug which has been shown to reduce brain metastasis growth in the laboratory.
- Trial name
- NCT02429570
- Testing
- Meclofenamate
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cognitive/Functional Effects, Metastatic Cancer
Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors
RATIONALE: Memantine may be able to decrease side effects caused by whole-brain radiation therapy. It is not yet known if memantine is effective in preventing side effects caused by whole-brain radiation therapy.
- Conditions
- Cognitive/Functional Effects, Metastatic Cancer, Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00566852
- Testing
- Memantine, Whole brain radiation therapy
- Where
- 235 sites in United States, Canada
- Volunteers
- 554 people
- Sponsor
- Radiation Therapy Oncology Group
Malignant Solid Tumor, Brain Metastasis
A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors
Brain metastasis represents one of the worst prognostic outcomes in advanced malignant tumors. Approximately 10% to 40% of patients with solid tumors develop brain metastases, a incidence rate significantly higher than that of…
- Trial name
- NCT07449481
- Testing
- Utidelone, Bevacizumab
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Glioblastoma, Brain Metastases
Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label Losartan Study
An open-label, single institutional phase II trial of losartan in patients with primary and metastatic brain tumors with an individual stepped-wedge, randomized, assessor-blinded, dose-finding design on three indications.
- Trial name
- ImPRESS (NCT03951142)
- Testing
- Losartan
- Where
- Norway
- Volunteers
- 165 people
- Sponsor
- Kyrre Eeg Emblem
Brain Metastases
Tumor Bed Hypofractionated IMRT After Surgery for Patients With Single,Large Brain Metastases From Solid Tumor
Investigators designed a study of a multimodality approach: surgery followed by hypofractionated intensity modulated radiation therapy (IMRT) using VMAT approach for patients with single, large brain metastases from solid primary…
- Trial name
- NCT02576522
- Testing
- brain metastatic patients
- Where
- Italy
- Volunteers
- 87 people
- Sponsor
- Istituto Clinico Humanitas
Brain Cancer, Neoplasm Metastases
Personalized Cellular Vaccine for Brain Metastases (PERCELLVAC3)
Cancer patients with brain metastases (BM) have poor prognosis. Current treatments produce limited efficacy. Recent advance in cancer immunotherapy has provided important new means to treat cancer patients at advanced stages.
- Trial name
- PerCellVac3 (NCT02808416)
- Testing
- Personalized cellular vaccine
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Guangdong 999 Brain Hospital
HER2 Mutation-Related Tumors, HER2
A Phase 1/1b Study of IAM1363 in HER2 Cancers
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
- Conditions
- HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer
- Trial name
- NCT06253871
- Testing
- IAM1363
- Where
- 53 sites in United States, France and 6 more
- Volunteers
- 383 people
- Sponsor
- Iambic Therapeutics, Inc